20 completed, 3 unknown, 1 recruiting. 24 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 20, Unknown 3, Recruiting 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Unknown 1 |
Follow Levodopa: new trials by email Literature Review of Levodopa trials Research Report on Levodopa
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. Administration of Carbidopa/levodopa - Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic | Phase 1 / Phase 2 | Recruiting | Julien Bally | 36 | 2025-07-18 | 2026-01-29 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in the Postprandial State in Healthy Chinese Subjects Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 36 | 2023-12-20 | 2023-12-22 |
| Bioequivalence Study of Entacapone,Levodopa and Carbidopa Tablets in Healthy Chinese Subjects Test (T) Entacapone,Levodopa and Carbidopa Tablets (II), Reference (R) Entacapone,Levodopa and Carbidopa Tablets (II) - Healthy | Phase 1 | Unknown | The Affiliated Hospital of Qingdao University | 68 | 2023-08-17 | 2023-08-04 |
| Bioavailability of Levodopa 250 mg and Carbidopa 25 mg With Regards to Reference Product Levodopa 250mg and Carbidopa 25mg Test Drug tablet, Levodopa 250mg and Carbidopa 25mg Referent Product tablet - Bioequivalence | Phase 1 | Completed | Laboratorios Andromaco S.A. | 44 | 2022-02-14 | 2022-03-08 |
| Measuring Parkinson's Disease Progression Levodopa - Parkinson's Disease | Phase 1 | Completed | Kevin J. Black, MD | 31 | 2017-10-19 | 2022-10-14 |
| Pharmacological Modulation of Belief Salience Placebo - Cap, L-dopa, Haloperidol - Haloperidol, Placebo | Phase 1 | Completed | King's College London | 30 | 2017-06-01 | 2019-10-10 |
| Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease NPC transplantation, Levodopa - Parkinson's Disease | Phase 1 / Phase 2 | Unknown | Chinese Academy of Sciences | 50 | 2017-05-01 | 2017-04-18 |
| Pharmacokinetic of Levodopa Study in Healthy Males Levodopa, carbidopa, ODM-104 - Parkinson Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2017-04-19 | 2017-09-26 |
| Dose-finding Pharmacokinetic Study in Healthy Males Levodopa, Carbidopa, ODM-104 - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 56 | 2017-02-21 | 2021-05-27 |
| Pharmacokinetic Study in Healthy Volunteers levodopa, carbidopa, ODM-104, levodopa, carbidopa, entacapone - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 15 | 2015-08-01 | 2016-01-14 |
| A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Levodopa/Carbidopa (Sinemet) - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 6 | 2015-04-01 | 2015-07-01 |
| Pharmacokinetic Study in Healthy Males levodopa, carbidopa, ODM-104 - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2014-11-01 | 2015-02-18 |
| Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury SPINALON (buspirone + levodopa + cardidopa) - Spinal Cord Injury | Phase 1 / Phase 2 | Completed | Nordic Life Science Pipeline Inc. | 50 | 2013-07-01 | 2015-08-20 |
| A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients Levodopa/carbidopa solution for SC administration, Placebo - Parkinson's Disease | Phase 1 | Completed | NeuroDerm Ltd. | 8 | 2012-12-16 | 2024-05-01 |
| Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE) L-dopa / carbidopa / entacapone (LCE) - Cocaine Abuse | Phase 1 | Completed | New York State Psychiatric Institute | 15 | 2010-08-01 | 2018-05-21 |
| Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics BIA 9-1067 5 mg, BIA 9-1067 25 mg, levodopa/carbidopa 100/25 - Parkinson's Disease (PD) | Phase 1 | Completed | Bial - Portela C S.A. | 74 | 2010-02-01 | 2015-12-24 |
| Levodopa Concentration Profile With Stalevo 75/125 mg Stalevo (levodopa/ carbidopa/ entacapone), Sinemet (levodopa/carbidopa) - Parkinson's Disease | Phase 1 | Completed | Orion Corporation, Orion Pharma | 20 | 2009-12-01 | 2010-08-13 |
| A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics Safinamide + Levodopa, Placebo + Levodopa - Idiopathic Parkinson's Disease | Phase 1 / Phase 2 | Completed | Newron Pharmaceuticals SPA | 24 | 2009-09-01 | 2013-03-29 |
| Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550) SCH 420814 10 mg, SCH 420814 100 mg, Placebo - Parkinson Disease | Phase 1 | Completed | Merck Sharp & Dohme LLC | 12 | 2009-04-21 | 2018-11-07 |
| Pharmacokinetic Interaction Between BIA 9-1067 and Standard-release Levodopa/Carbidopa BIA 9-1067, Sinemet® 100/25 mg - Parkinson Disease | Phase 1 | Completed | Bial - Portela C S.A. | 18 | 2009-03-01 | 2015-12-22 |
Showing 20 of 24. Sign in to see all of them.
Parkinson Disease (14) · Angelman Syndrome (1) · Cocaine-Related Disorders (1) · Paraplegia (1) · Quadriplegia (1) · Shy-Drager Syndrome (1) · Spinal Cord Injuries (1) · Tourette Syndrome (1)
Orion Corporation, Orion Pharma (6) · Bial - Portela C S.A. (3) · NeuroDerm Ltd. (2) · The Affiliated Hospital of Qingdao University (2) · Boston Children's Hospital (1) · Chinese Academy of Sciences (1) · Julien Bally (1) · Kevin J. Black, MD (1) · King's College London (1) · Laboratorios Andromaco S.A. (1) · Merck Sharp & Dohme LLC (1) · New York State Psychiatric Institute (1) · Newron Pharmaceuticals SPA (1) · Nordic Life Science Pipeline Inc. (1) · Washington University School of Medicine (1)
Finland (5) · United States (4) · Canada (2) · China (1) · France (1) · Germany (1) · India (1) · Israel (1) · Italy (1) · Portugal (1) · Switzerland (1) · United Kingdom (1)
Kevin J Black, MD (2) · Mika Scheinin, MD (2) · Yu Cao (2) · Adam Bisaga, M.D. (1) · Denis Strugala, DR.med. (1) · Eric Sicard, MD (1) · Kimmo Ingman (1) · Mohan Radhakrishna, MD (1) · Philip Evans, MBChB, MRCS (1) · Pierre Guertin, Ph.D. (1) · Wen-Hann Tan, BMBS (1) · Zhou Qi, Doctor (1)
PMID 12505794, PMID 16929307, PMID 20057930, PMID 26336641, PMID 29910127
P50DA009236 (1), R01MH073856 (1)